| 000 | 00917 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250513153338.0 | ||
| 264 | 0 | _c19990129 | |
| 008 | 199901s 0 0 eng d | ||
| 022 | _a0012-6667 | ||
| 024 | 7 |
_a10.2165/00003495-199856030-00001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Hogezand, R A | |
| 245 | 0 | 0 |
_aThe future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease. _h[electronic resource] |
| 260 |
_bDrugs _cSep 1998 |
||
| 300 |
_a299-305 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aVerspaget, H W | |
| 773 | 0 |
_tDrugs _gvol. 56 _gno. 3 _gp. 299-305 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00003495-199856030-00001 _zAvailable from publisher's website |
| 999 |
_c9741978 _d9741978 |
||